Cargando…

Severe pediatric asthma therapy: Dupilumab

Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrante, Giuliana, Tenero, Laura, Piazza, Michele, Piacentini, Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723147/
https://www.ncbi.nlm.nih.gov/pubmed/36483465
http://dx.doi.org/10.3389/fped.2022.963610
_version_ 1784844101380734976
author Ferrante, Giuliana
Tenero, Laura
Piazza, Michele
Piacentini, Giorgio
author_facet Ferrante, Giuliana
Tenero, Laura
Piazza, Michele
Piacentini, Giorgio
author_sort Ferrante, Giuliana
collection PubMed
description Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody against the Interleukin (IL)-4 receptor α-subunit that acts as an antagonist against both IL-4 and IL-13. Dupilumab binds the subunit of the IL-4 receptor, at the level of the subunit shared by the IL-13 receptor, blocking the inflammatory cascade of these two cytokines and the progression of the Th2-inflammatory pathway. The efficacy and safety of dupilumab have been investigated in recently published randomized controlled trials including pediatric patients with asthma. Currently, its use in asthma is approved in adults, adolescents, and children with severe asthma with type 2 inflammation, that are not controlled in spite of high-dose inhaled corticosteroids plus another maintenance drug. Studies are warranted for the evaluation of long-term treatment with dupilumab, including steroid sparing effect and discontinuation of treatment. Further research should also be planned in order to investigate dupilumab potential ability to interfere with the natural history of atopy since early childhood.
format Online
Article
Text
id pubmed-9723147
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97231472022-12-07 Severe pediatric asthma therapy: Dupilumab Ferrante, Giuliana Tenero, Laura Piazza, Michele Piacentini, Giorgio Front Pediatr Pediatrics Severe asthma is a rare disease affecting <5% of children with asthma. This group of patients account for about 50% of the costs of healthcare for children with asthma. Nowadays, several biological agents are available for pediatric severe asthma. One of these is dupilumab, a monoclonal antibody against the Interleukin (IL)-4 receptor α-subunit that acts as an antagonist against both IL-4 and IL-13. Dupilumab binds the subunit of the IL-4 receptor, at the level of the subunit shared by the IL-13 receptor, blocking the inflammatory cascade of these two cytokines and the progression of the Th2-inflammatory pathway. The efficacy and safety of dupilumab have been investigated in recently published randomized controlled trials including pediatric patients with asthma. Currently, its use in asthma is approved in adults, adolescents, and children with severe asthma with type 2 inflammation, that are not controlled in spite of high-dose inhaled corticosteroids plus another maintenance drug. Studies are warranted for the evaluation of long-term treatment with dupilumab, including steroid sparing effect and discontinuation of treatment. Further research should also be planned in order to investigate dupilumab potential ability to interfere with the natural history of atopy since early childhood. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9723147/ /pubmed/36483465 http://dx.doi.org/10.3389/fped.2022.963610 Text en © 2022 Ferrante, Tenero, Piazza and Piacentini. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Ferrante, Giuliana
Tenero, Laura
Piazza, Michele
Piacentini, Giorgio
Severe pediatric asthma therapy: Dupilumab
title Severe pediatric asthma therapy: Dupilumab
title_full Severe pediatric asthma therapy: Dupilumab
title_fullStr Severe pediatric asthma therapy: Dupilumab
title_full_unstemmed Severe pediatric asthma therapy: Dupilumab
title_short Severe pediatric asthma therapy: Dupilumab
title_sort severe pediatric asthma therapy: dupilumab
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9723147/
https://www.ncbi.nlm.nih.gov/pubmed/36483465
http://dx.doi.org/10.3389/fped.2022.963610
work_keys_str_mv AT ferrantegiuliana severepediatricasthmatherapydupilumab
AT tenerolaura severepediatricasthmatherapydupilumab
AT piazzamichele severepediatricasthmatherapydupilumab
AT piacentinigiorgio severepediatricasthmatherapydupilumab